delirium
Conditions
Interventions
Group of parecoxib:Parecoxib 40 mg (8 mg/ml) was injected intravenously before anesthesia induction
Group of Control:0.9%Nacl (5ml) was injected intravenously before anesthesia induction
Sponsors
Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with hyperlipidemia; 2. Age 18-100 years; 3. ASA I-III.
Exclusion criteria
Exclusion criteria: 1. Significant cognitive impairment before surgery; 2. History of craniocerebral trauma, psychiatric and neurological diseases; 3. History of antibiotic abuse; 4. Liver function Child-Pugh score >= 6; 5. Creatinine clearance < 30ml; 6. Hypersensitivity to the active ingredient of parecoxib sodium; 7. Long-term use of NSAIDs; 8. History of serious adverse drug reactions; 8. Patients with gastrointestinal bleeding or gastrointestinal perforation after treating NSAIDs; 9. Patients with active peptic ulcer or gastrointestinal bleeding, inflammatory bowel disease; 10. Patients who are in the third trimester of pregnancy or breastfeeding; 11. Patients with severe cardiovascular and cerebrovascular diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| delirium; | — |
Secondary
| Measure | Time frame |
|---|---|
| prostaglandin endoperoxide synthase 2, PTGS2;tumor necrosis factor, TNF-a;Interleukin- 6;Trimetlylamine oxide, TMAO;Interleukin-1ß;C reactive protein, CRP; | — |
Countries
China
Contacts
Public ContactXiaoxia Duan
Affiliated Hospital of Southwest Medical University
Outcome results
None listed